mohd izzuan Amgen has provided updated 2024 guidance with its revenue and non-GAAP EPS guidance ranges both including the consensus estimate. The biotech sees full-year revenue of $33B to $33.8B.
Consensus is $33.2B. Non-GAAP EPS is seen at $19.
20 to $20. Consensus is $19.51.
.
